Weinberg Uri
SEC CIK 1811030 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | Chief Innovation Off | 267.2K | — | $1.36M | 18 | 2021-07-06 | 2026-03-04 |
Most active insiders at NVCR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| 2 | Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| 3 | Paravasthu Mukund | COO | — | $693.8K |
| 4 | Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| 5 | Brackmann Christoph | CFO | — | $85.3K |
| 6 | Stafford Kristin | Dir | — | $46.4K |
| 7 | Ocean Allyson J | Dir | — | $46.4K |
| 8 | Scannell Timothy J | Dir | — | $46.4K |
| 9 | VERNON W ANTHONY | Dir | — | $46.4K |
| 10 | Hung David | Dir | — | $46.4K |
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-05 | 2026-03-03 | NVCR | NovoCure Ltd | Weinberg Uri | Chf Medical, Innovation Ofr | A - Grant | $0.00 | +50.1K | 273.6K | +22% | $0 |
| D | 2026-03-05 | 2026-03-04 | NVCR | NovoCure Ltd | Weinberg Uri | Chf Medical, Innovation Ofr | S - Sale | $13.31 | -6,412 | 267.2K | -2% | -$85.3K |
| 2026-03-03 | 2026-02-28 | NVCR | NovoCure Ltd | Weinberg Uri | Chf Medical, Innovation Ofr | A - Grant | $0.00 | +13.0K | 226.7K | +6% | $0 | |
| M | 2026-03-03 | 2026-02-27+ | NVCR | NovoCure Ltd | Weinberg Uri | Chf Medical, Innovation Ofr | S - Sale | $13.68 | -10.7K | 213.8K | -5% | -$146.9K |
| D | 2025-03-06 | 2025-03-04 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Innovation Off | A - Grant | $18.19 | +55.0K | 221.2K | +33% | +$1000.0K |
| 2025-03-04 | 2025-03-03 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Innovation Off | S - Sale | $18.92 | -268 | 166.2K | -0.2% | -$5,071 | |
| MA | 2025-03-03 | 2025-02-28 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Innovation Off | S - Sale | $18.75 | -4,637 | 166.8K | -3% | -$86.9K |
| M | 2025-03-03 | 2025-02-28 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Innovation Off | S - Sale | $18.75 | -4,637 | 166.8K | -3% | -$86.9K |
| D | 2024-02-29 | 2024-02-27 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Innovation Off | A - Grant | $16.30 | +81.8K | 171.1K | +92% | +$1.33M |
| 2023-07-06 | 2023-06-30 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Innovation Off | A - Grant | $35.28 | +305 | 89.3K | +0.3% | +$10.8K | |
| M | 2023-03-06 | 2023-03-03 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Innovation Off | A - Grant | $0.00 | +32.8K | 89.0K | +58% | $0 |
| D | 2023-03-02 | 2023-02-28 | NVCR | NovoCure Ltd | Weinberg Uri | Chief Innovation Off | A - Grant | $0.00 | +13.0K | 56.3K | +30% | $0 |
| DM | 2023-01-09 | 2023-01-05 | NVCR | NovoCure Ltd | Weinberg Uri | CSO | S - Sale+OE | $116.14 | -8,143 | 47.1K | -15% | -$945.8K |
| D | 2023-01-09 | 2023-01-05 | NVCR | NovoCure Ltd | Weinberg Uri | CSO | M - OptEx | $47.04 | +1,946 | 49.0K | +4% | +$91.5K |
| 2022-07-07 | 2022-07-05 | NVCR | NovoCure Ltd | Weinberg Uri | CSO | A - Grant | $59.08 | +281 | 49.5K | +0.6% | +$16.6K | |
| D | 2022-03-07 | 2022-03-03 | NVCR | NovoCure Ltd | Weinberg Uri | CSO | A - Grant | $0.00 | +17.4K | 49.2K | +55% | $0 |
| 2022-01-12 | 2022-01-06 | NVCR | NovoCure Ltd | Weinberg Uri | CSO | A - Grant | $63.82 | +35 | 31.8K | +0.1% | +$2,234 | |
| 2021-07-08 | 2021-07-06 | NVCR | NovoCure Ltd | Weinberg Uri | CSO | A - Grant | $137.12 | +113 | 31.8K | +0.4% | +$15.5K |
Purchase Sale Sale after option exercise All abbreviations